BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. Adv Ther 2018;35:1087-102. [PMID: 29949038 DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Grebely J, Dore GJ, Alami NN, Conway B, Dillon JF, Gschwantler M, Felizarta F, Hézode C, Tomasiewicz K, Fredrick LM, Dumas EO, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy 2019;66:73-9. [PMID: 30735896 DOI: 10.1016/j.drugpo.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
2 Beste LA, Green P, Berry K, Belperio P, Ioannou GN. Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. JAMA 2020;324:1003-5. [PMID: 32897335 DOI: 10.1001/jama.2020.10121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
3 Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, Dietz P, Mermin J, Ryerson AB. Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1:e186371. [PMID: 30646319 DOI: 10.1001/jamanetworkopen.2018.6371] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 21.0] [Reference Citation Analysis]
4 Wu T, Konyn PG, Cattaneo AW, Saab S. New Face of Hepatitis C. Dig Dis Sci 2019;64:1782-8. [PMID: 30756208 DOI: 10.1007/s10620-019-05511-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
5 Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang W, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin C, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial. Journal of Hepatology 2020;72:441-9. [DOI: 10.1016/j.jhep.2019.10.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 23.5] [Reference Citation Analysis]
6 Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021. [PMID: 34339561 DOI: 10.1111/jvh.13586] [Reference Citation Analysis]
7 Thomas E, Cheng WH, Dylla DE, Marx SE, Carabino J, Xu Q. Awareness and Epidemiology of Chronic Hepatitis C Virus Infections in Florida. Infect Dis Ther 2021. [PMID: 34914078 DOI: 10.1007/s40121-021-00578-5] [Reference Citation Analysis]
8 Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, Marx SE, Hayes OA, Manthena SR, Chirikov V, Dylla DE, Brooks H, Carabino JM, Saab S. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther 2021;38:5777-90. [PMID: 34704194 DOI: 10.1007/s12325-021-01928-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol 2020;72:1112-21. [PMID: 32061651 DOI: 10.1016/j.jhep.2020.01.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
10 Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, Curry MP, Tsai N, Wick N. Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection. Adv Ther 2020;37:2267-74. [PMID: 32279176 DOI: 10.1007/s12325-020-01301-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
11 Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther 2021;38:423-40. [PMID: 33145648 DOI: 10.1007/s12325-020-01535-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
12 Saab S, Kullar R, Khalil H, Gounder P. Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review. J Clin Gastroenterol 2021;55:250-7. [PMID: 32324677 DOI: 10.1097/MCG.0000000000001360] [Reference Citation Analysis]
13 Zankharia US, Kudchodkar S, Khoshnejad M, Perales-Puchalt A, Choi H, Ho M, Zaidi F, Ugen KE, Kim JJ, Weiner DB, Muthumani K. Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody. Hum Vaccin Immunother 2020;16:2156-64. [PMID: 32463327 DOI: 10.1080/21645515.2020.1763686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kahal D, Rutan GH; FAACP., FAACP. Epidemiology of Hepatitis C in Delaware. Dela J Public Health 2020;6:56-61. [PMID: 34467133 DOI: 10.32481/djph.2020.08.017] [Reference Citation Analysis]
15 Wedemeyer H, Erren P, Naumann U, Rieke A, Stoehr A, Zimmermann T, Lohmann K, König B, Mauss S. Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. Liver Int 2021;41:949-55. [PMID: 33592123 DOI: 10.1111/liv.14829] [Reference Citation Analysis]
16 Jang ES, Ki M, Choi HY, Kim KA, Jeong SH; Korean hepatitis epidemiology study group. The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015. Hepatol Int 2019;13:599-608. [PMID: 31432446 DOI: 10.1007/s12072-019-09975-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Adv Ther 2020;37:4033-42. [PMID: 32754824 DOI: 10.1007/s12325-020-01449-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
18 Pawlotsky J, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis 2020;40:392-402. [DOI: 10.1055/s-0040-1713657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Dionne-Odom J, Westfall AO, Dombrowski JC, Kitahata MM, Crane HM, Mugavero MJ, Moore RD, Karris M, Christopoulos K, Geng E, Mayer KH, Marrazzo J. Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living With Human Immunodeficiency Virus in the United States (2005-2016). Clin Infect Dis 2020;71:2405-13. [PMID: 31712815 DOI: 10.1093/cid/ciz1108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]